Egrifta (Tesamorelin) Missed-Dose Protocol
Tesamorelin, sold under the brand name Egrifta SV, is a synthetic growth hormone-releasing hormone (GHRH) analog. It is FDA-approved for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, given as a 2 mg subcutaneous injection once daily. It is not the same molecule as growth hormone itself, and it is not approved for general weight loss or for use outside HIV-associated fat redistribution.
If you miss a dose, skip it and take your next injection at your usual time the following day. Do not inject two doses to make up for the miss. This is the instruction in the FDA-approved prescribing information, which directs patients not to give two doses within a 24-hour period. Because tesamorelin's visceral-fat effect builds gradually over weeks of repeated growth hormone (GH) pulses rather than depending on any single injection, one missed dose does not meaningfully change the treatment's trajectory. A repeating pattern of missed doses is a different matter, since it can blunt the cumulative effect the drug relies on and is worth raising with your prescriber.
The evidence boundary, stated plainly
Established, from the FDA label: tesamorelin has a short plasma half-life (on the order of tens of minutes), is dosed once daily, requires no titration, and should not be double-dosed within 24 hours. The label also sets an IGF-1 threshold (repeat levels well above the age-adjusted upper limit of normal) as a reason to discontinue.
Plausible but not label-specified: exact timing cutoffs for "how late is too late" to take a delayed dose, an exact adherence percentage below which efficacy drops, and an exact number of missed doses that requires an IGF-1 recheck. These are reasonable clinical inferences, not printed instructions.
Not established from the material available to us: precise percentage figures for visceral fat reduction, side-effect rates, or cardiovascular risk ratios tied to lipodystrophy. The source publications describing the pivotal trials exist, but the specific identifiers available to us could not be verified against the underlying papers, so we are not repeating exact numbers here. If you want those figures, ask your prescriber to walk through the trial data directly, or request the current FDA label, which summarizes the pivotal trial results in its clinical studies section.
Why an occasional missed dose is pharmacologically forgiving
Tesamorelin binds GHRH receptors on pituitary somatotrophs and triggers a burst of endogenous GH release, similar in shape to the body's own naturally pulsatile GH secretion. That GH pulse drives a rise in IGF-1 and, over time, favors lipolysis in visceral fat depots more than in subcutaneous fat. This is a cumulative, tissue-level effect that plays out over weeks to months of consistent dosing, not a threshold effect tied to any single injection.
Contrast this with medications where missing one dose creates an immediate gap in protection, such as antiretrovirals during active viral replication. Tesamorelin is not that kind of drug. Skipping one dose means one fewer GH pulse is added to your body's ongoing endogenous rhythm; it does not reverse fat loss already achieved, and the endogenous GH-IGF-1 axis continues to function on its own between doses.
Timing rules if you remember late
The FDA label does not publish a specific "how many hours late is too late" cutoff. In its absence, the practical, conservative approach used across similar once-daily peptide therapies is:
- Remembered within a few hours of your usual time: it is reasonable to take the dose and resume your normal schedule the next day, as long as you are not close to your next scheduled dose.
- Remembered later in the day, close to your next scheduled dose: skip the missed dose entirely and resume at your normal time.
- Not sure which applies to you: ask your prescriber. They may set a specific cutoff based on your IGF-1 levels, side-effect history, and how your dosing schedule is structured.
This is site-level judgment applied to a gap in the label, not a labeled instruction, and it should not override a specific instruction your own prescriber has given you.
What repeated or extended gaps mean
A gap of a few days is unlikely to meaningfully reverse fat reduction already achieved, since the underlying tissue change developed slowly and would be expected to reverse slowly as well if the drug were stopped altogether. Extended discontinuation (not just a missed dose or two) is a different scenario, and available extension data from the pivotal trials describe gradual visceral fat re-accumulation after stopping tesamorelin, though we cannot state an exact timeline or magnitude here without directly verifying the source publication.
Tesamorelin does not require a titration period. If you resume after a gap of any length, the standard approach is to resume at the same 2 mg daily dose rather than restarting at a lower dose.
Missed-dose and monitoring conversation guide
Bring these points up with your doctor when discussing tesamorelin treatment, but follow their specific guidance for your situation rather than relying on this information alone.
| Situation | What the label supports | What is clinical judgment, not label text | When to contact your prescriber |
|---|---|---|---|
| Single missed dose, remembered same day | Skip if close to next dose; do not double up within 24 hours | Whether a same-day "make-up" dose is appropriate depends on how many hours remain until the next scheduled dose | Not urgent; mention at next visit |
| Two to three consecutive missed doses | No label instruction on this specific pattern | Resume at the usual 2 mg dose without titration; no evidence supports skipping ahead to a lower or higher dose | Call if it happens again, or if you cannot identify why doses were missed |
| Extended gap (roughly a week or more) | Label supports resuming at the same dose | Whether to recheck IGF-1 after resuming is a judgment call some prescribers make, not a labeled requirement | Call before resuming; ask whether a recheck makes sense for you |
| Missed doses due to side effects (joint pain, swelling, hand numbness or tingling) | Label lists these as reported adverse effects | Whether to continue, adjust timing, or stop depends on severity and your overall risk profile | Call promptly; do not simply keep skipping doses without telling your prescriber |
| IGF-1 result above the age-adjusted upper limit of normal | Label supports discontinuation if IGF-1 is repeatedly well above range | How to interpret a borderline single result is individualized | Call before your next injection |
| Planned interruption (surgery, illness, travel) | No titration needed to stop or restart | Timing the pause around a procedure is a shared decision with your surgical and prescribing teams | Discuss in advance, not the day of |
| Signs of a serious allergic reaction (difficulty breathing, facial or throat swelling, widespread rash) | Not a routine missed-dose scenario | This is outside the scope of missed-dose planning | Seek urgent or emergency care immediately |
The boundary running through this table is consistent: the FDA label tells you not to double-dose and not to titrate on restart. Everything about exact hour cutoffs, whether to recheck labs after a specific gap length, and how to weigh side effects against continued dosing is individualized judgment that belongs to you and your prescriber, not a printed rule.
How tesamorelin works, briefly
Tesamorelin is a modified 44-amino-acid GHRH analog. The modification extends its plasma half-life relative to native GHRH, which is what allows a single daily subcutaneous injection to produce a usable pituitary GH response. After injection, GH rises over roughly the first hour, then IGF-1 rises over the following hours, and the downstream lipolytic effect in visceral fat accumulates with repeated daily dosing. Limb (subcutaneous) fat is relatively preserved compared with visceral fat in the trials supporting approval, which is part of why tesamorelin is described as having some specificity for visceral adipose tissue rather than acting as a general fat-loss agent.
Adherence, not a single missed injection, is the variable most likely to determine whether a patient experiences the visceral fat reduction seen in the trials that led to approval. That framing, more than any single missed-dose rule, is the one worth carrying into a conversation with your prescriber if adherence has been inconsistent.
Reconstitution and practical adherence notes
Egrifta SV is supplied as a lyophilized powder reconstituted with the diluent provided in the kit. The label instructs use of the reconstituted solution promptly rather than storing it in the refrigerator for later use. Practical steps that reduce missed doses include tying the injection to an existing daily habit (a meal or bedtime routine), rotating injection sites to reduce site reactions, and using a daily reminder (alarm or medication app). These are general adherence strategies used across self-injected therapies; we are not aware of tesamorelin-specific adherence trial data that we can verify and cite here.
Contraindications and populations requiring extra caution
Tesamorelin is contraindicated in pregnancy because of theoretical effects of GH-axis activity on fetal growth, and it has not been established as safe or effective in patients under 18. Patients with active malignancy, or a history of pituitary disease, should discuss tesamorelin's appropriateness with their prescriber before starting or restarting after a gap, since GH-axis stimulation is a mechanistic concern in those settings even though we are not aware of tesamorelin-specific outcome data addressing it directly. This is a reason to ask, not a reason to assume the drug is unsafe for you.
When to contact your prescriber
Call your prescribing clinician if you have missed three or more consecutive daily doses, if side effects such as joint pain, swelling, or hand numbness are causing you to skip doses on your own, if you are having trouble with reconstitution, if you have an upcoming surgery or procedure, or if a recent IGF-1 result was above your expected range and you are unsure whether to resume. Seek urgent or emergency care instead of waiting for a routine callback if you experience signs of a serious allergic reaction, such as difficulty breathing or swelling of the face or throat.
Frequently asked questions
What should I do if I miss a dose of Egrifta (tesamorelin)? Skip the missed dose and take your next injection at your usual time the next day. Do not inject two doses within 24 hours.
Can I take a double dose to make up for a missed one? No. The label specifically instructs against giving two doses in one 24-hour period, and there is no evidence that doubling improves outcomes; it mainly raises the chance of an exaggerated GH/IGF-1 pulse.
Will missing one dose undo my visceral fat reduction? A single missed dose is not expected to meaningfully reverse fat reduction that developed over weeks of consistent dosing. Extended discontinuation is a different scenario and should be discussed with your prescriber rather than assumed to be equivalent to a single miss.
Do I need to restart at a lower dose after missing several days? No. Tesamorelin does not require titration. The 2 mg daily dose is both the starting and maintenance dose.
What is tesamorelin's half-life, and why does that matter for missed doses? The FDA label describes a short plasma half-life, on the order of tens of minutes. This matters less for missed-dose planning than the fact that the biological effect (the GH pulse and subsequent IGF-1 rise) unfolds over hours, and the fat-reduction effect unfolds over weeks, so a single missed injection does not remove an ongoing drug level the way it would for a continuously-acting medication.
References
- Egrifta SV (tesamorelin) prescribing information, as referenced descriptively in this article; the specific FDA label archive link could not be verified and has been removed.
- General clinical understanding that adherence is a recognized driver of outcomes in body-composition pharmacotherapy; the specific source link could not be verified and has been removed.
Note for editorial review: the pivotal-trial percentage figures (visceral fat reduction, arthralgia and injection-site reaction rates, and the cardiovascular risk figure for HIV-associated lipodystrophy) that appeared in the prior draft could not be verified against a confirmed primary source in this pass and have been removed or generalized rather than restated. If the underlying Falutz et al. NEJM 2007 publication and its extension studies can be directly retrieved and checked, those figures can be restored with a verified citation.